MAPT and Alzheimer disease: This group defines the basal level of tau pathology that could develop in this transgenic model in the absence of tau seeds; and (ii) a positive control group in which 1-month-old Tg30tau mice received intracranial injection of h-AD and intraperitoneal injections of isotype control antibody.